Print

ZIOPHARM, Inc. Granted European Patent Allowance for Palifosfamide  
12/7/2011 6:23:44 AM

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled “Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents” with claims directed to pharmaceutical compositions of a novel DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos® or ZIO-201) and their use in treating cancer. A counterpart patent in the United States was issued in March 2010, with rights extending to 2029. The patent estate covering palifosfamide compositions, methods of use and methods of manufacture now include issued patents in the United States, Australia, Europe, New Zealand and South Africa, as well as pending applications in the United States and various foreign jurisdictions.
//-->